The Alzheimer’s Association joins insurers as the latest to call for CMS to implement a sweeping coverage policy for Aduhelm that would battle “barriers to appropriate and equitable access,” according ...
WASHINGTON — A new $56,000-a-year Alzheimer’s drug would raise Medicare premiums broadly, and some patients who are prescribed the medication could face copayments of about $11,500 annually, according ...
The release by the U.S. CMS of the final national coverage determination (NCD) for Biogen Inc.’s Alzheimer disease (AD) drug, Aduhelm (aducanumab), lit speculation on the meaning for others in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback